Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
ROCKVILLE, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present preliminary clinical data from the Phase 2a clinical trial in advanced urothelial (bladder) cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 annual meeting on Friday, February 9, 2018 in San Francisco (CA, USA).
Title: RX-3117, an Oral Hypomethylating agent to Treat Advanced Solid Tumors: Interim Results from an ongoing Phase 2a study in Advanced Urothelial Cancer (aUC)
Authors: Meghan Salgia, Sumanta K. Pal, Vincent M. Chung, Scott T. Tagawa, Joel Picus, Hani M. Babiker, Sumati Gupta and Rexahn Pharmaceuticals.
Session Date/Time: Poster Session B: Friday, February 9: 12:15 PM-1:45 PM PST and 6:00 PM-7:00 PM PST: Board K8
A copy of the poster being presented will be available to be viewed on the Company's website at https://rexahn.com/cms/media-center/publication/posters/ beginning at 10:00 AM Eastern Time on Friday, February 9, 2018.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in Phase II clinical development: RX-5902 (Supinoxin™), RX-3117, and Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
LifeSci Advisors, LLC